Loading
Nonmelanoma Skin Cancer Studies · Journal article
Current Trends in Pharmacy and Pharmaceutical Chemistry · September 7, 2026
Raises a question worth testing. It does not answer one.
This scoping review synthesizes case reports and preliminary clinical studies suggesting that topical imiquimod may benefit selected oral premalignant lesions via immune stimulation, but explicitly acknowledges the evidence base as limited and calls for well-designed trials. No quantified lesion-clearance rates, transformation rates, recurrence data, or long-term safety outcomes are reported.
Scoping review. Oral premalignant lesions (OPMDs) across case reports and preliminary clinical studies; exact inclusion criteria and study selection process not detailed in text.. Intervention: Topical imiquimod for oral premalignant lesions.
Imiquimod activates Toll-like receptor 7 and nuclear factor kappa-B, promoting interferon-alpha, interferon-gamma, tumour necrosis factor-alpha, and interleukin release Case reports and preliminary clinical studies suggest potential benefit in oral dysplasia, leukoplakia, erythroplakia, and actinic cheilitis Common local adverse effects include erythema, oedema, erosion, pain, pruritus, and irritation; systemic effects are uncommon
Long-term safety and efficacy data explicitly identified as missing and necessary for clinical decision-making Common local adverse effects include erythema, oedema, erosion, pain, pruritus, and irritation; systemic effects are uncommon
Clinicians should view imiquimod as a potentially useful adjunctive, minimally invasive option for selected oral premalignant lesions where surgery is unsuitable, but should recognize that no rigorous efficacy or safety data yet support its routine use. Controlled trials are urgently needed before widespread adoption.
A scoping review of case reports and preliminary studies suggesting potential benefit of imiquimod for oral premalignant lesions, but with explicitly limited evidence and no controlled trial data or transformation outcomes reported.
As stated by the source record.
Clinicians should view imiquimod as a potentially useful adjunctive, minimally invasive option for selected oral premalignant lesions where surgery is unsuitable, but should recognize that no rigorous efficacy or safety data yet support its routine use. Controlled trials are urgently needed before widespread adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Oral potentially malignant disorders (OPMDs) are mucosal conditions associated with an increased risk of oral squamous cell carcinoma, accounting for over 90% of oral cancers. In 2005, the World Health Organization recommended the term “potentially malignant disorders” to clarify classification of oral lesions at risk of malignant transformation. Common OPMDs include leukoplakia, erythroplakia, oral submucous fibrosis, actinic cheilitis, oral lichen planus, and selected inherited disorders. As malignant transformation cannot be predicted reliably, management requires regular clinical surveillance, counselling to address risk factors including tobacco and alcohol, and biopsy to identify dysplasia or occult carcinoma. Nevertheless, a negative biopsy does not exclude dysplasia elsewhere in the mucosa or future transformation. There is therefore a need for effective, minimally invasive preventive therapies that can complement surgical management.Imiquimod is an imidazoquinolinamine immune-response modifier with antiviral and antitumour activity. It activates Toll-like receptor 7 and nuclear factor kappa-B, promoting the release of interferon-alpha, interferon-gamma, tumour necrosis factor-alpha, and interleukins. These actions recruit plasmacytoid dendritic cells, enhance natural-killer-cell and macrophage activity, and promote a T-helper type 1 immune response; imiquimod may induce tumour-cell apoptosis. Its established topical indications include external anogenital warts, actinic keratosis, and superficial basal cell carcinoma.Case reports and preliminary clinical studies suggest that topical imiquimod may benefit carefully selected oral precancerous lesions, including oral dysplasia, leukoplakia, erythroplakia, and actinic cheilitis. Its non-invasive administration, local immune stimulation, and tolerable adverse-effect profile may make it useful when surgery is unsuitable or undesirable. Common local reactions include erythema, oedema, erosion, pain, pruritus, and irritation, while systemic effects are uncommon. Mucoadhesive delivery systems may improve mucosal retention, controlled drug release, and bioavailability. Although findings are promising, the evidence base remains limited. Well-designed clinical trials are needed to establish optimal formulations and treatment schedules, safety, lesion-clearance rates, recurrence patterns, and long-term effects on malignant transformation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.